Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.

Park UC, Shin JY, Kim SJ, Shin ES, Lee JE, McCarthy LC, Newcombe PJ, Xu CF, Chung H, Yu HG.

Retina. 2014 Feb;34(2):288-97. doi: 10.1097/IAE.0b013e3182979e1e.

PMID:
23842101
2.

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.

Cruz-Gonzalez F, Cabrillo-Estévez L, López-Valverde G, Cieza-Borrella C, Hernández-Galilea E, González-Sarmiento R.

Graefes Arch Clin Exp Ophthalmol. 2014 Mar;252(3):469-75. doi: 10.1007/s00417-014-2585-7. Epub 2014 Feb 13.

PMID:
24522370
3.

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.

Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI.

Ophthalmology. 2012 Nov;119(11):2304-11. doi: 10.1016/j.ophtha.2012.05.040. Epub 2012 Jul 26.

PMID:
22840423
4.

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.

Hermann MM, van Asten F, Muether PS, Smailhodzic D, Lichtner P, Hoyng CB, Kirchhof B, Grefkes C, den Hollander AI, Fauser S.

Ophthalmology. 2014 Apr;121(4):905-10. doi: 10.1016/j.ophtha.2013.10.047. Epub 2013 Dec 21.

PMID:
24365177
5.

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, Baird PN, Guymer RH.

Ophthalmology. 2013 Jan;120(1):115-21. doi: 10.1016/j.ophtha.2012.10.006. Epub 2012 Nov 11.

PMID:
23149126
6.

CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.

McKibbin M, Ali M, Bansal S, Baxter PD, West K, Williams G, Cassidy F, Inglehearn CF.

Br J Ophthalmol. 2012 Feb;96(2):208-12. doi: 10.1136/bjo.2010.193680. Epub 2011 May 10.

PMID:
21558292
7.

Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.

Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N.

Am J Ophthalmol. 2012 Jul;154(1):125-36. doi: 10.1016/j.ajo.2012.01.010. Epub 2012 Apr 1.

PMID:
22465368
8.

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PN.

Ophthalmology. 2013 Aug;120(8):1641-8. doi: 10.1016/j.ophtha.2013.01.014. Epub 2013 Apr 9.

PMID:
23582991
9.

Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.

Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.

Am J Ophthalmol. 2014 May;157(5):1013-21. doi: 10.1016/j.ajo.2014.01.019. Epub 2014 Jan 30.

PMID:
24487050
10.

Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.

Ophthalmology. 2012 Aug;119(8):1621-7. doi: 10.1016/j.ophtha.2012.02.022. Epub 2012 May 1.

PMID:
22551738
11.

Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.

Mathew R, Richardson M, Sivaprasad S.

Am J Ophthalmol. 2013 Apr;155(4):720-6, 726.e1. doi: 10.1016/j.ajo.2012.11.003. Epub 2013 Jan 11.

PMID:
23317653
12.

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.

Park UC, Shin JY, McCarthy LC, Kim SJ, Park JH, Chung H, Yu HG.

Mol Vis. 2014 Dec 19;20:1680-94. eCollection 2014.

13.

Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population.

Yuan D, Yuan D, Liu X, Yuan S, Xie P, Liu Q.

Ophthalmologica. 2013;230(4):227-32. doi: 10.1159/000355068. Epub 2013 Sep 25.

PMID:
24080590
14.

Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.

Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.

Retina. 2013 Mar;33(3):467-73. doi: 10.1097/IAE.0b013e3182753b2a.

PMID:
23400082
15.
16.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
17.

Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).

Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Aitchison R, Erlich SS; MONET Clinical Study Group.

Ophthalmology. 2012 Sep;119(9):1867-73. doi: 10.1016/j.ophtha.2012.03.043. Epub 2012 Jun 8.

PMID:
22683252
18.

Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.

Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U.

Retina. 2014 May;34(5):860-7. doi: 10.1097/IAE.0000000000000007.

PMID:
24756034
19.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group.

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
20.

Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients.

Shin JY, Yu HG.

Retina. 2014 Dec;34(12):2359-66. doi: 10.1097/IAE.0000000000000225.

PMID:
25011025
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk